Fructose metabolism has been implicated in various diseases, including metabolic disorders, neurodegenerative disorders, cardiac disorders, and cancer. However, the limited availability of a quantitative imaging radiotracer has hindered its exploration in pathology and diagnostic imaging. We adopted a molecular design strategy based on the catalytic mechanism of aldolase, a key enzyme in fructolysis. We successfully synthesized a radiodeoxyfluorinated fructose analog, [F]4-fluoro-4-deoxyfructose ([F]4-FDF), in high molar activity. Through heavy isotope tracing by mass spectrometry, we demonstrated that C-deoxyfluorination of fructose led to effective trapping as fluorodeoxysorbitol and fluorodeoxyfructose-1-phosphate in vitro, unlike C- and C-fluorinated analogs that resulted in fluorolactate accumulation. This observation was consistent in vivo, where [F]6-fluoro-6-deoxyfructose displayed substantial bone uptake due to metabolic processing whereas [F]4-FDF did not. Importantly, [F]4-FDF exhibited low uptake in healthy brain and heart tissues, known for their high glycolytic activity and background levels of [F]FDG uptake. [F]4-FDF PET/CT allowed for sensitive mapping of neuro- and cardioinflammatory responses to systemic lipopolysaccharide administration. Our study highlights the significance of aldolase-guided C radiodeoxyfluorination of fructose in enabling effective radiotracer trapping, overcoming limitations of C and C radioanalogs toward a clinically viable tool for imaging fructolysis in highly glycolytic tissues.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2967/jnumed.123.266905 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!